Adrian Senderowicz - 16 Jun 2022 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)

Reporting relationship: Director
Issuer ticker: PBYI
Reported as of: 16 Jun 2022
Net transaction value: -$73,303
SEC form: 4
Accepted by SEC: 21 Jun 2022, 21:55:01 UTC
Prior SEC filing: 17 Jun 2022
Next SEC filing: 15 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Adrian Senderowicz

Filing notes and source

Key filing fact

Adrian Senderowicz filed Form 4 for PUMA BIOTECHNOLOGY, INC. (PBYI) on 21 Jun 2022.

Key facts

This page summarizes Adrian Senderowicz's Form 4 filing for PUMA BIOTECHNOLOGY, INC. (PBYI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 Jun 2022, 21:55.

Change

Previous filing in this sequence was filed on 17 Jun 2022.
Current net transaction value: -$73,303.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PBYI transaction

Common Stock

Sale

Transaction value: $73,303
Shares: -27,858
Change %: -51%
Price: $2.63
Shares after: 27,000
Date: 16 Jun 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares were sold pursuant to a Rule 10b5-1 trading plan.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.554 to $2.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.